Schulhoff & Co’s Avadel Pharmaceuticals AVDL Stock Holding History

Schulhoff & Co’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-137,500	Closed	-$2.1M	–	133
2025 Q3	$2.1M	Hold	137,500	–	–	0.9%	33
2025 Q2	$1.22M	Hold	137,500	–	–	0.54%	45
2025 Q1	$1.08M	Buy	137,500 +500	+0.4%	+$4.19K	0.48%	51
2024 Q4	$1.44M	Hold	137,000	–	–	0.53%	41
2024 Q3	$1.8M	Hold	137,000	–	–	0.75%	35
2024 Q2	$1.93M	Hold	137,000	–	–	0.87%	27
2024 Q1	$2.31M	Buy	137,000 +41,000	+43%	+$611K	1.01%	25
2023 Q4	$1.36M	Hold	96,000	–	–	0.65%	43
2023 Q3	$989K	Hold	96,000	–	–	0.5%	50
2023 Q2	$1.58M	Hold	96,000	–	–	0.74%	39
2023 Q1	$879K	Hold	96,000	–	–	0.41%	56
2022 Q4	$687K	Hold	96,000	–	–	0.32%	62
2022 Q3	$480K	Hold	96,000	–	–	0.25%	70
2022 Q2	$234K	Buy	96,000 +35,000	+57%	+$144K	0.11%	101
2022 Q1	$416K	Hold	61,000	–	–	0.18%	78
2021 Q4	$492K	Hold	61,000	–	–	0.2%	73
2021 Q3	$597K	Hold	61,000	–	–	0.27%	68
2021 Q2	$410K	Hold	61,000	–	–	0.18%	80
2021 Q1	$551K	Hold	61,000	–	–	0.25%	69
2020 Q4	$407K	Hold	61,000	–	–	0.2%	76
2020 Q3	$307K	Buy	+61,000	New	+$444K	0.17%	80

Other funds holding AVDL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GJL

Gendell Jeffrey L $11.3B AUM 163.05% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Schulhoff & Co's AVDL Position: Q4 2025 in Review

Schulhoff & Co sold out of Avadel Pharmaceuticals (AVDL) in Q4 2025, closing a stake of 137,500 shares — an estimated $2.1M sold.

Schulhoff & Co first reported a position in AVDL in Q3 2020 and held it in 21 quarters. The position peaked at $2.31M in Q1 2024. 207 funds tracked by Wall St. Rank hold AVDL as of Q4 2025.

Schulhoff & Co reported no remaining Avadel Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Schulhoff & Co sold 137,500 Avadel Pharmaceuticals shares in Q4 2025, an estimated $2.1M.
Schulhoff & Co first reported a position in Avadel Pharmaceuticals in Q3 2020 and held it in 21 quarters.
Schulhoff & Co's Avadel Pharmaceuticals position peaked at $2.31M in Q1 2024.
207 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2025.

Based on Schulhoff & Co's 13F filing for Q4 2025, filed 11 Feb 2026.